September 26, 2017 6:37 PM ET


Company Overview of Avelas BioSciences, Inc.

Company Overview

Avelas BioSciences, Inc. is a clinical stage biotechnology company that focuses on developing technologies that advance care for cancer surgery and therapeutic intervention. It develops AVB-620, an intravenously administered in vivo fluorescent protease-activatable peptide that detects, marks, and diagnoses cancer. The company was incorporated in 2008 and is based in La Jolla, California.

11099 North Torrey Pines Road

Suite 290

La Jolla, CA 92037

United States

Founded in 2008





Key Executives for Avelas BioSciences, Inc.

Chief Executive Officer, President and Director
Age: 41
Co-Founder and Research Collaborator
Age: 65
Chief Medical Officer
Clinical Advisor
Age: 48
Compensation as of Fiscal Year 2017.

Avelas BioSciences, Inc. Key Developments

Avelas Biosciences, Inc. Doses First Patient in Phase 2 Study of AVB-620 in Women with Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Avelas Biosciences, Inc. announced that, the first patient has been dosed in its Phase 2 clinical trial of AVB-620 in women with primary, nonrecurrent breast cancer undergoing surgery. This open-label, single-arm, Phase 2 study of AVB-620 is designed to evaluate 100 patients during two separate trial periods. Period 1 will have approximately 30 patients to evaluate conditions to achieve maximal differences in fluorescent signals between malignant and nonmalignant tissue. Period 2 will assess approximately 70 patients to test dosing and imaging conditions determined in Period 1, and the accuracy of AVB-620 imaging data to distinguish between malignant and nonmalignant tissues.

Avelas BioSciences, Inc. Presents at JMP Securities Life Sciences Conference 2017, Jun-20-2017 01:00 PM

Avelas BioSciences, Inc. Presents at JMP Securities Life Sciences Conference 2017, Jun-20-2017 01:00 PM. Venue: St. Regis Hotel, 2 East 55 Street, New York, New York, United States. Speakers: Carmine N. Stengone, Chief Executive Officer, President and Director.

Avelas Biosciences Appoints Steven Chen as Chief Medical Officer

Avelas Biosciences, Inc. announced the appointment of Steven Chen, M.D., as chief medical officer of the company. Dr. Chen originally joined Avelas Biosciences in July 2014 as the vice president of clinical affairs. Dr. Chen previously served as the chief of breast surgery at UC Davis Medical Center, followed by a position as an associate professor of surgery and as the associate program director of the surgical oncology training program at City of Hope National Medical Center in Duarte, California.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Private Placement
March 31, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Avelas BioSciences, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at